Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

GLAALPHA COMBINATION OPHTHALMIC SOLUTION [SIN17265P]

Active ingredients: GLAALPHA COMBINATION OPHTHALMIC SOLUTION

View product's general information
Last updated 24 April 2026

Product Info

GLAALPHA COMBINATION OPHTHALMIC SOLUTION

[SIN17265P]

Product information

Active Ingredient and Strength

BRIMONIDINE TARTRATE - 1 MG/ML
RIPASUDIL HYDROCHLORIDE HYDRATE EQV. RIPASUDIL - 4 MG/ML

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

KOWA COMPANY, LTD., MOHKA FACTORY - JAPAN

Registration Number

SIN17265P

Licence Holder

DKSH SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01EA55

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

GLAALPHA is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

Dosing

4.2 Posology and method of administration

Posology
Use in adults, including the elderly
Instill one drop at a time, twice a day.

Use in pediatric population
No clinical studies have been conducted to evaluate the efficacy and safety in pediatric patients (see Section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Method of Administration

  1. Route of administration: Instillation only.

  2. When dispending the drug: Instruct patients on the following:

    1. In the instillation, the patient should open the affected eye, instill the drug into the conjunctival sac, close the eyelid for 1 to 5 minutes while compressing the lacrimal part, and open the eye.

    2. Be careful during the instillation to avoid direct contact of the tip of the container with the eye in order to prevent contamination of the drug.

    3. Instill with an interval of at least 5 minutes when using the drug in combination with other ophthalmic solutions.

Contraindications

4.3 Contraindications

GLAALPHA is contraindicated in patients with a history of hypersensitivity to any of the components of GLAALPHA (see Section 2 and 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
GLAALPHA is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.